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Phosphatidylserine is a global immunosuppressive
signal in efferocytosis, infectious disease, and cancer
RB Birge*,1,10, S Boeltz*,2,10, S Kumar1,10, J Carlson3,10, J Wanderley4,10, D Calianese1,10, M Barcinski5,10, RA Brekken6,7,10, X Huang6,7,10,
JT Hutchins3,10, B Freimark3,10, C Empig3,10, J Mercer8,10, AJ Schroit9,10, G Schett2,10 and M Herrmann*,2,10
Apoptosis is an evolutionarily conserved and tightly regulated cell death modality. It serves important roles in physiology by sculpting
complex tissues during embryogenesis and by removing effete cells that have reached advanced age or whose genomes have been
irreparably damaged. Apoptosis culminates in the rapid and decisive removal of cell corpses by efferocytosis, a term used to distinguish
the engulfment of apoptotic cells from other phagocytic processes. Over the past decades, the molecular and cell biological events
associated with efferocytosis have been rigorously studied, and many eat-me signals and receptors have been identified. The
externalization of phosphatidylserine (PS) is arguably the most emblematic eat-me signal that is in turn bound by a large number of
serum proteins and opsonins that facilitate efferocytosis. Under physiological conditions, externalized PS functions as a dominant and
evolutionarily conserved immunosuppressive signal that promotes tolerance and prevents local and systemic immune activation.
Pathologically, the innate immunosuppressive effect of externalized PS has been hijacked by numerous viruses, microorganisms, and
parasites to facilitate infection, and in many cases, establish infection latency. PS is also profoundly dysregulated in the tumor
microenvironment and antagonizes the development of tumor immunity. In this review, we discuss the biology of PS with respect to its
role as a global immunosuppressive signal and howPS is exploited to drive diverse pathological processes such as infection and cancer.
Finally, we outline the rationale that agents targeting PS could have significant value in cancer and infectious disease therapeutics.
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Facts
 PS externalization during apoptosis and cell stress
are mediated by scramblases Xkr8 and TMEM16,
respectively.
 Exposed PS is an evolutionarily conserved anti-inflam-
matory and immunosuppressive signal.
 An astonishing number of pathogens causing major
infectious diseases utilize PS and apoptotic mimicry to
evade host immune responses.
 PS signaling is highly dysregulated in the tumor micro-
environment and autoimmune diseases.
 PS-targeting therapeutics (e.g., AnxA5, bavituximab) can
stimulate immune activity.
Open Questions
 Is PS dysregulation a universal mechanism of immune
evasion for bacteria, viruses and protists?
 Should PS targeting be considered a global therapeutic
option for infectious diseases?
 Should PS be considered a global checkpoint inhibitor for
cancer?
 Are all PS signaling equally immunosuppressive?
 Are cofactors involved?
Many critical biochemical pathways require the presence of
specific phospholipid classes in the inner and outer leaflet of
the plasma membrane. Virtually all eukaryotic cells have an
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asymmetric distribution of phospholipids across their bilayer
membrane, where the choline-containing phospholipids,
phosphatidylcholine (PC) and sphingomyelin are predomi-
nately maintained on the outer membrane leaflet, and the
amino-phospholipids (phosphatidylserine (PS) and phos-
phatidylethanolamine (PE)) are predominately localized in
the inner membrane leaflet.1 This asymmetry is actively
maintained by the regulated activity of ATP-dependent lipid
transporters. However, membrane asymmetry collapses
under a variety of physiological and pathological conditions
resulting in dramatic changes in the biochemical properties
of the membrane. For example, the redistribution of PS to
the external face of the plasma membrane flags cells for
their recognition, phagocytosis,2 and ultimate degradation by
phagocytes (efferocytosis). Moreover, the interaction between
PS-expressing cells and immune cells elicits profound
immunological consequences by triggering immunosuppres-
sive pathways that prevent both local and systemic immune
activation. Although these pathways are used by apoptotic
cells to quell potential immune sequelae against ‘self’, these
same pathways are hijacked by pathogens and tumors to
promote their sinister life-threatening expansion. Taken
together, these observations suggest that PS functions as
an upstream immune checkpoint that suppresses the devel-
opment of immunity. This raises the possibility that PS
blockade by the therapeutic administration of PS-targeting
agents can restore pathogen and tumor immunity.
PS Asymmetry in Biological Membranes
PS, the most abundant negatively charged glycerophospho-
lipid in eukaryotic membranes, is comprised of a glycerol
backbone esterified at the sn-1 and sn-2 carbons of the
glycerol moiety with two fatty acyl chains of variable length and
saturation, and a phosphate linkage at the sn-3 position
(Figure 1).3 Compared with related phospholipids PC and PE,
the distinguishing feature of PS is the covalent attachment
of serine to the phosphate, giving PS a net negative charge
on the head group. Like other glycerophospholipids, PS is
synthesized at specialized intracellular structures called
mitochondrial-associated membranes (MAMs), structural
and functional domains located between the mitochondria
and endoplasmic reticulum (ER) that contain enzymes
involved in calcium and innate immune signaling, and
phospholipid biosynthesis.4 In higher mammals, PS synthesis
occurs by two homologous enzymes, phosphatidylserine
synthase 1 (PTDSS1) and PTDSS2, both localized in MAMs
that appear to have partially redundant activity. Although
knockout of either enzyme in mice have unremarkable
phenotypes, double PTDSS1/PTDSS2 knockout mice fail to
produce PS and is embryonically lethal.5,6 In contrast, yeast
deficient in PTDSS (encoded by a singleCHO1 gene) are able
to survive when grown on high concentrations of ethanol-
amine,7 suggesting that PS is an essential membrane lipid in
higher metazoans. Interestingly, genetic linkage analysis
suggest that rare sporadic dominant gain-of-function muta-
tions in PTDSS1 occur in patients with Lenz-Majewski
syndrome, biochemically characterized by increased PS in
their membranes, and phenotypically by multiple congenital
abnormalities of generalized craniotubular hyperostosis.8
Following biosynthesis, PS is transported from MAMs
to the plasma membrane by carrier proteins where it is
actively maintained on the inner leaflet of the membrane by
several complementary enzymes. Flippases and Floppases
translocate phospholipids from the outer to the inner surface
and from the inner to the outer surface, respectively.
Scramblases collapse membrane asymmetry thereby rando-
mizing all phospholipid species between leaflets, which in the
context of PS biology, effectively increases the accumulation
of PS on the external side of the membrane.3
Physiologically, the intracellular deposition of PS has
structural and biochemical importance.8 The net negative
charge of PS contributes structurally to membrane curvature
and fluidity, and the electrostatic charge provides a docking
site for proteinswith poly-cationic domains such asC2 andGla
domains.9 Indeed, a number of important intracellular proteins
require PS for proper localization and/or activation. Such
proteins include the E3 ubiquitin-ligase NEDD4, protein kinase
C isoforms, several phospholipase C and D isoforms,
Figure 1 Molecular structure of PS and major biosynthetic and degradative pathways: (a) PS is comprised of a glycerol backbone esterified at the sn-1 and sn-2 carbons of
the glycerol moiety with two fatty acyl chains of variable length and saturation, as well as a phosphate linkage at the sn-3 position covalently linked to serine (a). In eukaryotic cells,
PS is synthesized from phosphatidylcholine (PC) and phosphatidylethanolamine (PE) by PSS1 and PSS2, respectively, and can be catabolized by phosphatidylserine
decarboxylase (PSD) to generate PE. (b) During apoptosis and cell stress, PS is externalized to the outer surface of the plasma membrane, where it can be detected by
fluorophores such as FITC-annexin Vor GFP-lactadherin 3 (green). Red staining indicates Rhod-2AM that monitors intracellular Ca2+ levels, which are elevated during apoptosis
and during cell stress
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phosphatase, and tenson homology-deleted on chromosome
10, as well as a number of synaptotagmin isoforms that are
required for vesicle trafficking and fusion. In addition, several
members of the annexin family of proteins, which have
essential roles in membrane–cytoskeletal anchoring and
membrane trafficking, bind PS.9 Upon loss of membrane
asymmetry, PS translocates across the bilayer and interacts
with a new set of extracellular serum proteins and PS
receptors that trigger an array of biochemical and immunolo-
gical responses.
Although PS externalization is clearly one of the emblematic
signals that tags cells for efferocytosis, PS is also externalized
on activated platelets during coagulation and platelet aggre-
gation,10 on viable monocytes,11 on the surface of mature
macrophages,12 on myocytes during myoblast fusion,13 on
nuclei expelled from reticulocytes,14 on activated B cells,15
on tumor cells,16 on extracellular vesicles derived from cancer
cells,17 and on the surface of exosomes derived from tumors,
platelets and dendritic cells (DCs).18 However, PS exposure
on viable cells does not induce phagocytosis as both amateur
and professional phagocytes are able to distinguish between
living and apoptotic PS-exposing cells.
Mechanisms of PS Externalization during cell Stress and
Apoptosis
Although the biochemical landscape for PS externalization is
still incomplete, recent progress in this area has emerged
following the cloning and characterization of two novel
scramblases; transmembrane protein 16F (TMEM16F)19 and
Xkr8 (ced-8),20 that externalize PS by distinct regulatory
mechanisms. TMEM16F is an eight transmembrane domain
receptor with aminophospholipid scramblase activity that is
critical for calcium-dependent externalization of PS in acti-
vated platelets. The importance of TMEM16F in platelet
activation was obtained from knockout studies showing that
loss of function impairs calcium-dependent PS scramblase
activity. This resulted in the inability of platelets to recruit and
activate clotting factors with PS-binding Gla domains that
include factor V, factor X, and prothrombin.21 Loss-of-function
mutation in TMEM16F is associated with Scott’s syndrome, a
rare bleeding disorder characterized by defects in calcium-
dependent phospholipid scrambling, suggesting that it is the
predominant scramblase for externalizing PS in platelets.19,21
Other members of the TMEM16 family, that include 16C, 16D,
16F, 16G, and 16J have been shown to scramble PS, although
it awaits clarification in which cell types, and by what activation
signals, these scramblases function.22
More recently, a second scramblase, Xkr8, was shown to
cause PS externalization in cells dying by apoptosis. In
contrast to TMEM16F, Xkr8 is not activated by Ca2+, but via a
caspase 3/7-dependent pathway. In fact, Xkr8 scramblase
activity is very low in living cells, but is activated during
apoptosis through a conserved Asp-Glu-Val-Asp-Gly caspase
3/7-cleavage site motif located at its C termini that releases an
inhibitory sequence thereby activating scramblase activity.20
Interestingly, Xkr8 is a mammalian homolog of the CED8 in
Caenorhabditis elegans.23 Mutated CED8 leads to a charac-
teristic defect in efferocytosis suggesting evolutionary con-
servation of PS externalization pathways in apoptosis. Other
members of the Xkr family have been defined, including Xkr4
and Xkr9 that are also activated by caspases, for example,
caspase 3.24 Unlike Xkr8 that is ubiquitously expressed, Xkr4
and Xkr9 have tissue-specific inducible expression patterns.
This suggests that PS externalization might be dynamically
regulated by specific signaling pathways that impact the
expression of Xkr4 or Xkr9.
Not all Externalized PS is Functionally Equivalent
The discussion above highlights an important conceptual idea
that different PS scramblases react to distinct upstream
signals to externalize PS. Adding complexity to PS biology, it
is now apparent that not all externalized PS is functionally
equivalent. In the above-mentioned scenario for Xkr8 and
TMEM16 that are activated by caspase 3 and Ca2+,
respectively, only the former serves as an eat-me signal for
PS receptors and efferocytosis. Indeed, when a mutant
TMEM16F was introduced into a mouse lymphoma cell
(W3-Ildm) to achieve constitutive PS exposure, PS-positive
tumor cells (assessed as annexin V positive) were not
engulfed by professional DCs, and only became phago-
cytosed after activation of caspase 3 and Xkr8 with Fas
antibody.25 Thus, the PS externalized by TMEM16 does not
provide an eat-me signal, but is sufficient to provide an
electrostatic charge to recruit clotting factors via the inter-
actions of their Ca2+-dependent Gla domains. Moreover, the
Ca2+-stimulated PS externalization induced by TMEM16F is
rapid (within minutes) and reversible upon restoration of Ca2+
homeostasis,22 while Xkr8-mediated PS exposure is slow
(within hours) and irreversible (Figure 2).
With respect to the externalization of PS by Xkr8 during
apoptosis, recent evidence suggests that stable and irrever-
sible PS externalization is achieved by a dynamic interplay
between Xkr8 and ATPase, class VI, type 11C (ATP11C), a
member of the P4-type ATPase family of flipases that redirects
PS from the outer membrane leaflet back to the inner leaflet.26
Similar to Xkr8, ATP11C contains a caspase cleavage site, but
unlike Xkr8 that is activated by caspase cleavage, ATP11C is
inactivated by the same process and prevents return of PS to
the inner leaflet. Conversely, when cells express ATP11C with
a mutated caspase recognition site, cellular flipase activity
remains high, and cells expressing mutant ATP11C do not
sustain PS externalization or retain their ability to be engulfed.
In the non-apoptotic context, a high Ca2+ concentration
activates TMEM16, but does not inactivate ATP11C, possibly
explaining the reversibility of TMEM16-mediated PS
externalization.
The preceding reasoning suggests that a critical concentra-
tion or topology of PS may need to be acquired for recognition
as an eat-me signal. A possible explanation as to how PS
topology or local density might be recognized differently by PS
receptors might also be related to the PS clustering activity
exerted by Annexin.27 The combination of low membrane
fluidity and consequent low clustering of PS receptors on
the phagocytes’ surface due to reduced lateral mobility of the
PS molecule may help to distinguish dead/dying from viable
PS-exposing cells.11 Receptor clustering is often sufficient
to activate intracellular signaling cascades. In apoptotic cells
the cytoskeleton and the focal adhesion molecules are early
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targets of caspases. After death receptor stimulation, active
caspase 8 immediately translocates to plectin, a major
cytoskeletal cross-linking protein and quantitatively cleaves it
at Asp 2395.28 The resulting weakening of the cytoskeleton
increases the lateral mobility of PS and might consequently
enable cooperative binding of PS ligands or receptors.
Furthermore, there is evidence that lipid rafts and PS are
mutually exclusive on the membranes of apoptotic cells in
contrast to viable and activated cells.29 This suggests that
there may be different topologies of PS arranged on the
surfaces of apoptotic versus viable cells that engage receptors
in distinct ways. Indeed, recent studies examining the effects
of ligand-density on the activation of AXL receptor tyrosine
kinase (Axl; a PS receptor) support this idea, in which it was
concluded that the specific sensing of ligand spatial distribu-
tion is a critical feature for PS-dependent (Axl) receptor
activation.30
Although the preceding sections have focused on the
interplay between scramblases, flipases, and PS externaliza-
tion, other enzymes and pathways have been implicated in
PS externalization including the ATP-binding cassette (ABC)
transporter ABC131 and Tat1.32 Moreover, studies by Lee
et al.32 suggest that increases in bidirectional membrane
trafficking results in PS externalization. In their model, PS is
externalized by a two-step process whereby internalization of
plasma membrane into cytoplasmic vesicles occurs as cells
shrink during apoptosis. This is followed by Ca2+-dependent
trafficking of PS-positive vesicles back to the cell surface.32
Whether these specialized forms of PS externalization lead to
diverse depots of PS on the membrane is not clear, although
the recent development of high-resolution fluorescent probes,
such as Disciodin-C2, and GFP-LactadherinC2, should
make it more feasible to visualize PS in discrete subcellular
membrane domains and topologies.33
The realization that not all externalized PS has the same
biological function also highlights the need to better char-
acterize the nature of the molecular species of PS on the cell
surface. Identification of the PS fatty acyl composition, its
saturation, length, and oxidative status by mass spectrometry
might be instructive in determining whether different externa-
lization itineraries lead to discrete species of PS. With respect
to the idea of PS oxidation, in which one or more of the acyl
chains has unsaturated and oxidized substitutions, there is
some evidence that oxidized PS (oxPS) is a more efficient
eat-me signal than the non-oxidized molecule.34 Also some
PS-binding proteins involved in efferocytosis (i.e., Gas6, milk
fat globule-EGF factor 8 protein (MFG-E8), and T-cell
immunoglobulin and mucin domain receptor-1 (TIM-1))
appear to bind with higher affinity to oxPS,34 which tends to
protrude from the planar layers of cell membranes. This is
interesting from a mechanistic view, as one of the proposed
pathways for PS oxidation involves cytochrome c-dependent
PS oxidation, with cytochrome c acquiring a gain-of-function
peroxidase activity once released from mitochondria.35 In this
model, cytochrome c released during mitochondrial outer
membrane permeabilization would serve two interrelated
functions. First, as a central component of the apoptosome,
and second, to concomitantly catalyze the oxidation of PS to
provide an eat-me assurance signal for efferocytosis.36 As
discussed below, one of the most important future goals will
be to assess whether all forms of externalized PS are
immunosuppressive.
Figure 2 Models for the different forms of PS externalization: As noted in the text, PS can be externalized under a variety of physiological and patho-physiological conditions
that include platelet activation (a) and caspase-dependent apoptosis (b). (a) Activated platelets promote a Ca2+-TMEM16-mediated externalization of PS that serves as a
nucleation scaffold for the recruitment of hemostasis factors that initiate blood clotting (indicated by the solid black line in a). (b) Apoptotic cells externalize PS via the caspase 3/7-
mediated cleavage of Xkr8 that serves as an eat-me signal for various PS receptors (TAMs, TIMs, and αvβ5 and αvβ3 integrins). Recent studies suggest that during apoptosis,
the surface density of the PS may reach a critical threshold that clusters and activates PS receptors. Why PS externalized on apoptotic cells (Xkr8-dependent) serves as a signal
for efferocytosis, while PS expressed on stressed and activated cells (TMEM16-dependent) has not been completely elucidated
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Immunological Consequences of PS; Homeostasis,
Autoimmunity, and Cancer
The externalization of PS on apoptotic cells serves as a pre-
eminent eat-me signal for efferocytosis and allows the
controlled elimination of damaged, infected, activated, or
senescent cells that would otherwise release potentially
harmful cellular contents. The translocation of phospholipids
in cellular membranes, for example, PS exposure on the cell
surface and cardiolipin translocation within the mitochondrial
membranes, are key events in the initial phases of apoptosis
and correlate with other major hallmarks of dying cells that
include plasma membrane blebbing, cell shrinkage, loss of
mitochondrial membrane potential, caspase activation, chro-
matin condensation, DNA fragmentation, and cytoskeleton
remodeling. Collectively, these events are genetically pro-
grammed, and are characterized by non-inflammatory and
non-immunogenic outcomes that maintain tolerance. Indeed,
it has been known for almost two decades that apoptotic cells
are potently immunosuppressive.37 In contrast, if the clear-
ance of apoptotic cells fails, they may enter the stage of
secondary necrosis, a condition involved in the etiology38 and
pathology39 of chronic inflammatory autoimmune diseases. It
is also known that post-apoptotic remnants in the germinal
centers of lymph nodes can serve as selecting antigens for B
cells that have acquired auto-reactivity during the process of
somatic mutation.38 IgG auto-antibodies recognizing second-
ary necrotic cells (SNEC) or apoptotic cell-binding ligands are
able to shift silent clearance toward inflammation.40
At the tissue and systemic level, the rapid non-inflammatory
and non-immunogenic clearance of apoptotic cells involves at
least three kinds of interrelated pathways that signal; (i) ‘find
me’, (ii) ‘eat me’, and (iii) ‘tolerate me’. With respect to ‘find me’
or attraction signals, apoptotic cells actively release chemo-
attractants recruiting phagocytes to the site of cell death. The
best understood of these factors involve phospholipids such
as lysophosphatidylcholine and sphingosine-1-phosphate
as well as other mediators (e.g., nucleoside triphosphate
with purinergic receptor Y, CX3CL1/fractalkine, endothelial
monocyte-activating polypeptide II, and dimeric ribosomal
protein S19 with G-protein coupled receptor CD88 and
thrombospondin-1 (reviewed in ref. 41)). At the same time,
secreted ‘stay away signals’ that repel neutrophils, limit the
immunogenic damage caused by degranulation.42 Together,
these signals ensure that a phagocytic system is available in
the neighborhood of dying cells. Indeed, all of the major
phagocytic cell types; that is, macrophages, DCs, Kupffer
cells, microglia, and alveolar macrophages have receptors for
apoptotic find-me signals, ensuring that secondary necrosis,
and the ensuing immunogenic outcomes resulting from the
rupture of the plasma membrane, is minimized.
PS is one of the primary apoptotic cell ligands that provides
eat-me signals to phagocytes. Upon recruitment, phagocytes
recognize PS directly or indirectly through cell–cell interac-
tions mediated by specific bridging or adapter molecules
recruited to the surfaces of dying cells. Macrophages
recognize additional abnormal cell characteristics such as
elevated lateral mobility of PS11 or modifications of the
glycocalyx.43 These interactions initiate signaling pathways
that rearrange the actin cytoskeleton thereby enabling the
engulfment of apoptotic cells.44
Finally, the rapid and effective removal of apoptotic cells by
phagocytes is crucial for prevention of an undesirable inflam-
matory response and maintenance of an anti-inflammatory
status during homeostasis (‘tolerogenic signals’), a term that
has sometimes been called silent apoptosis to convey immune
downregulation. In contrast to the uptake of pathogens or FcR-
mediated phagocytosis, engulfment of apoptotic cells does not
induce inflammatory cytokine production. Instead, engulfed
apoptotic cells induce the secretion of the anti-inflammatory
cytokine interleukin-10 (IL-10) and TGF-β and simultaneously
decrease the secretion of the inflammatory cytokines TNF-α,
IL-1β, and IL-12.37,45 Moreover, in vitro experiments have
shown that the production of TGF-β, considered a central
player in the anti-inflammatory responses of phagocytes, is
increased following efferocytosis. Indeed, phagocytes that
engulf PLB-985 cells, human monomyelocytes that do not
express PS during apoptosis, fail to produce TGF-β, whereas
incubation of the phagocyteswith PS liposomes, or PS directly
transferred onto the PLB-985 surface membranes, restored
TGF-β secretion.45 This indicates that PS functions as an
immune-suppressing mediator during the clearance of
apoptotic cells.
Consequences of a Failure in Apoptotic Cell Clearance
As noted above, the silent clearance of apoptotic cells is
carried out by a reliable phagocytic system that allows rapid
recognition and removal in a non-immunogenic and non-
inflammatory manner. However, this system, at times, can fail.
If clearance is impaired, apoptotic cells can undergo second-
ary necrosis and cause the release of pro-inflammatory
cytokines by phagocytes.40 SNEC, characterized by the loss
of membrane integrity, release large amounts of modified
intracellular and intranuclear macromolecules as well as ions
into the surrounding interstitium. In this case, apoptotic cells
gain inflammatory potential similar to certain primary necrotic
cells increasing the possibility that an immune response can
be developed against these neo-epitopes.44
Multiple studies support a direct link between a failure
of apoptotic cell clearance and the development of the
chronic autoimmune disease systemic lupus erythematosus
(SLE).38,46 First, as reported almost 20 years ago, macro-
phages isolated from patients with SLE display a reduced
capacity for phagocytosis of apoptotic cell remnants in vitro.46
Second, in lymph node sections from some patients with SLE,
the number of macrophages containing ingested apoptotic
material is decreased.38 Third, in the same patients, binding of
apoptotic nuclear remnants to follicular DCs was observed.
This could contribute to the etiology of autoimmunity by
supplying survival signals to B cells that have accidentally
developed auto-reactivity against nuclear and apoptosis-
related autoantigens during somatic diversification, a process
that randomly inserts mutations into the variable region of
IgG.38 Taken together, these observations provide evidence
for clearance deficiency as one of the etiological causes of
SLE. Furthermore, impaired clearance of apoptotic cells leads
to the secretion of anti-nuclear antibodies from auto-reactive B
cells. These antibodies form immune complexes with nucleic
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acid containing apoptotic cell remnants that are cleared by
peripheral blood monocytes, macrophages and DCs through
Fcγ-R-mediated phagocytosis. Upon Fcγ-R clustering, vast
amounts of inflammatory cytokines47 are released leading to
chronic inflammatory disease and ultimately to multiple organ
damage.40
PS Receptors, Efferocytosis, and Surveyors of Immune
Homeostasis
During the past decade, great strides have been gained in the
identification and characterization of PS receptors and PS-
binding opsonins (endogenous proteins that bridge PS to
efferocytes). This has increased our understanding of how
apoptotic cells are removed in tissues. There is now definitive
evidence from knockout mice demonstrating that effective PS-
dependent clearance protects organisms from secondary
necrosis. Mice deficient in individual PS receptors, for
example, Mertk, TIM-3, SCARF-1, as well as PS opsonizing
proteins MFG-E8, C1q, or Protein S, exhibit a failure in the
clearance of apoptotic cells and the subsequent elevation in
pro-inflammatory cytokines such as IL-1β and TNF-α.48 These
observations convincingly link PS recognition by PS receptors
with removal of immunogenic debris that prevents autoimmu-
nity (discussed above).
With over a dozen PS receptors and opsonins that span a
wide range of gene families, there are likely to be overlapping
and non-overlapping mechanisms whereby PS receptors can
invoke immune suppression and tolerance. These effects
could be passive and indirect, by ensuring efficient efferocy-
tosis that safeguards against secondary necrosis and the
release of signals associated with danger-associated mole-
cular patterns that activate Toll-like receptors (TLRs). Con-
versely, PS receptors can also function as direct inhibitory
receptors that dampen inflammation and/or induce immune
suppression. Among this latter group, the inhibitory TAM and
TIM receptors are among the best-studied PS receptors.
The TAM receptor tyrosine kinases (Tyro3, Axl, and Mertk)
and their cognate ligands, Gas6 and Pros1, are essential
in the resolution of inflammation, and have direct anti-
inflammatory activity that suppresses nuclear factor-κB
(NF-κB) and inflammatory cytokines. In the case of Mertk,
which is abundantly expressed on M2macrophages and bone
marrow-derived DCs (BMDCs), the tyrosine kinase transmits a
PS-dependent inhibitory signal that prevents LPS-inducible
phosphorylation of IκB kinase, degradation of IκB, and the
activation of NF-κB.49 This effect is Mertk-specific, as BMDCs
from Mertk−/− mice fail to show inhibition of NF-κB activation.
These effects on NF-κB inhibition are separable from those
on efferocytosis,50 an observation consistent with previous
findings that binding of apoptotic cells to the surface of
phagocytes is sufficient for the downregulation of inflamma-
tory cytokines51 (Figure 3).
Studies with the related TAM receptor Axl provides further
mechanistic insight into how PS receptors transmit immune
inhibitory signals. Unlike Mertk that is constitutively expressed
on macrophages and DCs, under basal conditions the
expression of Axl in DCs is low, but is significantly upregulated
as a consequence of TLR engagement to resolve and break
inflammation in anticipation of the end of an inflammatory
cycle.52 At a mechanistic level, Gas6-induced activation of Axl
suppresses TLR and type I interferon (IFN) receptor JAK-STAT
signaling by upregulating the expression of SOCS1 and
SOCS3, thereby turning off the expression of inflammatory
cytokines including TNF-α, IL-1β, and IFN-α.52 Teleologically,
a similar mechanism appears to operate in antigen-activated
T cells, whereby activated T cells upregulate Pros1 and drive a
PS/Tyro3-dependent inhibitory signal.53 Pros1− /− mice fail to
suppress T-cell activation, suggesting this mechanism is in
place to prevent T-cell over-activation.
Similar to the TAMs, the TIMs comprise another class of PS
receptors that directly relay inhibitory signals from PS.54–58 In
humans, there are three main subtypes of TIM receptors
(TIM-1, TIM-3, and TIM-4), each of which has confirmed PS
interactions through a conserved N-terminal IgV extracellular
domain. Although similar in structure (all are type I membrane
receptors), TIM receptors have unique features and are
expressed on different cell types. TIM-4 is the only receptor
of the family that does not harbor any intracellular tyrosine
phosphorylation motifs, suggesting it is a tethering molecule
that does not independently transmit a signal.59
Characterization of both TIM-1 and TIM-3 modulation of
T-cell responses have been described, and a detailed
signaling pathway downstream of activation of these receptors
is beginning to emerge. Out of the three receptors, TIM-3 has
been themost intensely studied with regard to cancer and viral
infection, as it is potently immunosuppressive when activated.
One active area of research is investigating the role of TIM-3 in
T-cell exhaustion, which is a defective T-cell response found
in many chronic infections and in cancer.60 In a recent study
investigating TIM-3 signaling pathways, Rangachari et al.61
found that HLA-B-associated transcript (Bat3), a chaperone
protein known to bind to the intracellular tail of TIM-3,
associates with the active domain of Lck. Agonistic antibody
ligation of TIM-3 led to the dissociation of Bat3, allowing active
Lck to associate with the cytoplasmic tail. These results are
consistent with studies showing interactions between TIM-3
and Lck, along with Src family tyrosine kinase Fyn.62
The mechanism resembles that of immunoreceptor tyrosine-
based inhibition motifs on inhibitory receptors (ITIMs). Other
studies suggest more complex actions of TIMs; for example,
TIM-3 expressed on tumor-associated DCs suppressed
TLR-mediated innate immune responses to nucleic acids by
interfering with HMGB1-mediated anti-tumor immune-
surveillance mechanisms.63 Although these studies provide
significant insight into the TIM-3 signaling pathway, there is still
much to be elucidated. For example, it is not known how IL-10
is upregulated during efferocytosis, and whether it is driven by
engagement of a PS receptor.
Consequences of Silent Clearance in Viral and Protist
Infection, and in Cancer
Although ‘silent clearance’ of the apoptotic cells is necessary
to maintain homeostasis, in cancer, exposure to radiation, and
some parasitic, viral and bacterial infections, the ubiquitous
mechanism of non-inflammatory apoptosis might be disad-
vantageous for the host. Indeed, pathogens involved in the
most severe infectious disease utilize PS exposure for silent
apoptosis to ensure their own survival. These aspects of PS
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biology are discussed in the subsequent sections and are
described in Figure 4 and Tables 1a and 1b.
Viruses Employ PS Externalization and Apoptotic
Mimicry to Evade Host Responses
As obligate intracellular pathogens, viruses have evolved
many elegant strategies that subjugate host cell factors and
functions to assure their successful entry and replication. It
has recently come to light that viruses use a strategy termed
viral apoptotic mimicry to hijack essential apoptotic recog-
nition and clearance mechanisms for their own means. This
mechanism, whereby viruses mimic apoptotic debris by
concentrating PS within their membranes (enveloped
viruses), or cloaking themselves in cell-derived PS-containing
vesicles (non-enveloped viruses), is emerging as a common
theme used by many virus families to facilitate virus binding,
entry, and immune evasion.64 Indeed, viral apoptotic mimicry
has proven to be a widespread lipid mediated entry mechan-
ism used by several enveloped viruses including: Vaccinia,
Pichinde, Cytomegalo, Lassa Fever, Lenti, Dengue, Ebola and
Marburg viruses, and non-enveloped viruses:64,65 SV40,
Hepatitis A, and Polio66,67 (Tables 1a and 1b). Given the
anti-inflammatory nature of apoptotic clearance, it is easy to
envision why a virus would evolve to use an apoptotic mimicry
strategy. In addition, as professional and non-professional
phagocytes are capable of clearing apoptotic debris and there
are multiple PS receptors, by using apoptotic mimicry viruses
may expand their cell-type specificity and tropism without the
need for specific receptor ligands.
For viruses using apoptotic mimicry, the acquisition of
envelope PS during virus assembly is critical. Viruses use
different means to acquire PS in a process that is largely
dependent upon the intracellular compartment in which they
replicate. For enveloped viruses this is achieved by budding
through intracellular organelles or from the plasmamembrane.
The luminal leaflet of the ER membrane, for example, is rich in
PS1,3 making it an obvious lipid source for viruses looking to
incorporate PS into their membranes. Two viruses using
apoptotic mimicry, dengue and vaccinia virus, are thought to
acquire their PS-rich membranes by budding into the ER
lumen.68 Human immunodeficiency virus (HIV), which uses
PS as cofactor for infection, acquires PS by budding from lipid
rafts.69 For non-enveloped viruses, PS acquisition relies
largely on hijacking of intracellular membranes including
multivesicular bodies and autophagy-like organelles that are
rich in PS.70
Although viral apoptotic mimicry was originally hypothe-
sized to be immune evasion strategy explaining the silent
infection employed by hepatitis B virus, this process was first
experimentally linked to the induction of poxvirus endo-
cytosis.71 The rational being that by mimicking an apoptotic
body, poxviruses hijack the indispensable apoptotic clearance
machinery of host cells to promote virus internalization.72
Since this initial finding, viral apoptotic mimicry has been found
to facilitate binding, entry and immune evasion by viruses
from 10 different families (reviewed in refs. 64 and 65). For
many of these viruses, the PS receptors and/or bridging
molecules they engage and the purpose for which they employ
apoptotic mimicry has been defined.
Figure 3 The PS receptor Mertk acts as an inhibitory receptor to promote homeostasis and tissue tolerance: Mertk, a member of the TAM family of PS receptors, interacts
with externalized PS on apoptotic cells via its bridging molecule Gas6 to drive efferocytosis and tissue tolerance. Once engaged, Mertk transmits an inhibitory signal that inhibits
NF-kB and the production of inflammatory cytokines from TLRs. Efficient efferocytosis also produces the production of tolerogenic factors such as IL-10 and TGF-β that tolerize
the local microenvironment in favor of M2 macrophages, immature DCs, and Tregs. When Mertk is targeted by knockout, or inhibited by therapeutics, TLR-induced activation of
inflammatory cytokines proceeds unabated in the absence of dampening signals, leading to an immunogenic environment characterized by the production of M1 macrophages,
antigen presenting mature DCs and CD8+ T cells as discussed throughout the text
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As discussed above, apoptotic clearance is intimately linked
with the dampening of inflammatory responses. This involves
the induction of anti-inflammatory cytokine production, as well
as inhibition of inflammatory cytokine secretion and TLR
signaling. Thus, in addition to promoting uptake and binding,
apoptotic mimicry by viruses potentiates infection by dampen-
ing host innate immune responses. An early indication of
this comes from a study of pseudotyped lentiviral particles
which, when complexed with Tyro3/Axl/Mer (TAM) bridging
molecules, Gas6 or Protein S, act as ‘super TAM agonists’ that
disable host immune responses and facilitate virus spread.73
In this study, the authors demonstrate that enhancement of
viral infection is associated with TAM-mediated inhibition of
type I IFN signaling. They found that BMDCs from TAM
knockout mice produced high levels of IFN-α, IFN-β, and
SOCS1 mRNA relative to WT BMDCs when challenged with
PS-containing pseudotyped lentiviral particles. In addition,
inclusion of anti-IFN α/β antibodies restored lentiviral infection
in TAM triple KO BMDCs nearly to the level of infection
seen in WT cells. These data suggest that enhancement of
viral infection promoted by TAM engagement is primarily due
to inhibition of the antiviral type I IFN response. In the case
of vaccinia, in vivo infection with vaccinia virus results in the
induction of anti-inflammatory cytokines including TGF-β and
IL-10, prevention of macrophage infiltration, and inhibition of
T-cell maturation.74
The prominent utility of apoptotic mimicry, including from
highly pathogenic viruses such as ebola and dengue
(Table 1a) begs the question – can viral apoptotic mimicry
be targeted therapeutically? Several lines of evidence suggest
this may be possible.75,76 Treatment of animals infected with
Pichinde virus with PS-targeting antibodies protected animals
from lethal viral infection in vivo.76 In vitro studies demon-
strated that PS-targeting antibodies potently inhibit HIV-1
infection of peripheral blood mononuclear cells by facilitating
upregulation of chemokines known to block receptors utilized
byHIV-1 for cell entry.77 In addition, in vitro studies have shown
that PS-targeting antibodies bind several enveloped viruses
and enveloped virus-infected cells, including ebola, influenza,
and vaccinia. Recent studies showing that PS is involved in
non-enveloped virus infections66 suggest that PS-targeting
antibodies could also be employed to treat such infections.
A recent report by Shibata et al.78 showed that Axl-targeting
antibodies attenuate influenza and RSV lethality in vivo
through modulation of innate immune responses. These
data suggest that several small compound inhibitors
directed against Axl and Mer that are in various stages of
pre-clinical/clinical development as cancer therapeutics might
also be therapeutically efficacious in viral infections. Collec-
tively, these results suggest that inhibition of PS-mediated host
responses by antibody targeting of PS could provide a new
class of antiviral therapeutics.
Bacteria Exploit Host Cell efferocytosis and use PS
Cloaking to Facilitate Cell-to-Cell Spread
Similar to viruses, bacteria also take advantage of effero-
cytosis in host cells to promote cell-to-cell spread. This
mechanism has recently been described in Listeria mono-
cytogenes.79 L. monocytogenes are extruded from the cell
membrane of infected macrophages packaged in PS-coated
vesicles, which then interact with TIM-4 on other macrophages
to facilitate their uptake and cell-to-cell spread. Other bacterial
pathogens that also appear to exploit efferocytosis and/or
Figure 4 Modalities of PS exposure on infectious agents: (a). Silent
Phagocytosis Clearance of PS-exposing particles (e.g., apoptotic remnants), via
silent phagocytosis of monocytes/macrophages. (b). Energy loss Diminished energy
reserves cause breakdown of membrane asymmetry and lead to PS exposure on
infected monocytes (e.g., HCV). Enveloped Virions budding from infected cells
expose PS. (c) Direct exposure of PS on HIV-1, Ebola, Variola and other highly
pathogenic enveloped viruses. (1) Replication and budding from PS-rich surfaces
(e.g., golgi apparatus, endoplasmic reticulum) allows PS exposure on newborn
virions. (2) Clusters of Enteroviruses are packed and released non-lytically in
PS-exposing lipid vesicles elevating their infectivity. (d) Bystander exposure of
PS (Trypanosoma brucei) T. brucei evolutive forms do not expose PS. Parasites are
engulfed as bystanders together with PS-exposing apoptotic cell remnants. (e) Trojan
horse (Leishmania) (1) Upon infection of the host PS-exposing Leishmania
promastigotes are engulfed primarily by neutrophils. (2) ‘Apoptotic’, PS-exposing
Leishmania promastigotes induce release of TGF-β by neutrophils silencing their
leishmanicidal response at the side of the sand-fly bite. (3) Infected PS-exposing
Neutrophils are silently phagocytosed by monocytes enabling intracellular replication.
Hiding of promastigotes in ‘apoptotic’ neutrophils not only delivers viable Leishmania
into macrophages but also delays the immune response against the parasite until the
first line neutrophilic response is resolved. (4) PS-exposing Leishmania promasti-
gotes can actively invade into monocytes for intracellular replication. (5) Persistent
infection and intracellular replication in the amastigote form within professional
phagocytes
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PS cloaking have been identified, such as Mycobacterium
tuberculosis, M. avium, M. marinum, and Chlamydia. Inter-
estingly, efferocytosis appears to be an effective mechanism
by which the host can keep Mycobacterium species under
control,80 highlighting the fine balance between host cell
defense and pathogen dispersal mechanisms. Whether or not
other bacterial species utilize efferocytosis and PS cloaking
generally to their advantage remains to be seen.
Protozoan Parasites Utilize PS and Apoptotic Mimicry to
Evade Host Immune Responses
In addition to viruses and bacteria, there is a growing body of
evidence that various protozoans also use PS for apoptotic
mimicry and immune subversion as a part of their infectious
lifecycle. However, the function of PS in protozoan infectivity is
complicated by the fact that protozoans can activate a
classical programmed cell death (PCD) pathway to externalize
PS, but also externalize PS to evade immune surveillance.
The regulatory pathways that govern these events are now
beginning to be unraveled (Figures 4 and 5).
Apoptotic-like death has been described in three different
species of trypanosomatids: Trypanosoma cruzi,81 Trypano-
soma brucei,82 and Leishmania amazonensis,83 etiological
agents of neglected endemic diseases that include Chagas’
disease, African trypanosomiasis and Leishmaniasis, respec-
tively. Following these reports, a large number of descriptions
of apoptosis and apoptosis-like cell death in pathogenic
and non-pathogenic unicellular organisms were reported.84
These different types of cell death were first described as
resulting from environmental stresses, suggesting that single
cell organisms, like higher metazoans, were programmed
for their cellular demise. For example, death of promastigotes
of Leishmania amazonesis, with apoptotic features, was
described upon treatment with the calpain inhibitor,
MDL28170.85 In addition, promastigote death and PS
exposure is inhibited by Z-VAD-FMK in stationary-phase
cultures.86 Indeed, with the exception of rhizaria, apoptotic
markers, including PS externalization, have been observed in
unicellular organisms of all major groups of prokaryotes.84
Collectively, these studies demonstrated that unicellular
organisms could undergo an apoptosis-like cell death program
with phenotypic features resembling apoptosis of multicellular
organisms (Figure 5).
The apparent conservation of apoptotic cell death machin-
ery in single cell protists raises several important questions.
What is the biochemical machinery that executes and controls
these events? What is the teleological significance of the
selective pressures that shape the evolution of apoptosis-like
death in these organisms and what benefit do they have on
population dynamics?87 Importantly, biochemical analysis of
the various components of different types of cell death
together with bioinformatics-based comparisons between
PCD pathways in the different species of the phylogenetic
evolutionary tree have found PCD-related sequences.88 The
phylogenetic distribution of such sequences indicates that the
PCD machinery operating in multicellular organisms had its
origin in the early stages of eukaryote evolution, suggesting
that death by apoptosis is phylogenetically conserved.84,89
In addition to the PCD in single cell protists, elegant studies
in Leishmania spp, and Leishmania amazonensis, have led to
a conceptual distinction between apoptotic death (in which the
organism dies) and apoptotic mimicry (in which the organism
mimics death to favor infectivity).90 In both situations, PS
exposure on the surface of the parasite has an important role
in host/parasite interaction. In amastigotes, the form respon-
sible for disease dissemination in mammalian hosts, humans
included, PS exposure without parasite death, has been
described and shown to be modulated by the host in a murine
model of the disease.90,91 On the other hand, in promasti-
gotes, a sub-population of metacyclic parasites die, displaying
several phenotype markers of apoptotic death, including PS
Table 1a List of viruses that employ apoptotic mimicry
Virus family Role of apoptotic mimicry Phosphatidylserine receptors
Enveloped viruses
Alphavirus (CHIKV, RRV, SINV, EEEV) Binding, endocytosis, and infection TIM-1, TIM-4, AXL, Integrins (MFG-E8 binding),
CD300A
Arenavirus (LASV, AMAV, TCRV, LCMV, Pichinde) Binding, endocytosis and infection AXL, Tyro3, TIM-1
Baculovirus Binding, endocytosis and infection AXL, TIM-1
Filoviriruses (EBOV, MARV) Binding, endocytosis, infection and
Immune evasion
AXL, Tyro3, TIM-1 TIM-4
Flavivirus (DENV, WNV, YFV) Binding, endocytosis, infection and
Immune evasion
TIM-1, TIM-3, TIM-4, AXL, Tyro3
Poxvirus (VACV MV and EV) Signaling, endocytosis and infection AXL
Rhabdovirus (VSV) Binding, endocytosis and infection AXL, TIM-1
Non-enveloped viruses
Enterovirus (PV) Infection Unknown
Hepatovirus (HAV) Unknown TIM-1
Polyomavirus (SV40) Binding, endocytosis and infection AXL
Abbreviations: AMAV, amapari virus; CHIKV, chikungunya virus; DENV, dengue virus; EBOV, ebola virus; EEEV, eastern encephalitis equine virus; HAV, hepatitis A
virus; LASV, lassa virus; LCMV, lymphocytic choriomeningitis virus; MARV, marburg virus; PV, poliovirus; RRV, Ross river virus; SINV, sindbis virus; SV40, simian
virus 40; TCRV, tacaribe virus; VACV MV and EV, vaccinia mature virion and extracellular virion; VSV, vesicular stomatitis virus; WNV, West Nile virus; YFV, yellow
fever virus
Listed are the virus families (viruses in parenthesis) experimentally demonstrated to use apoptotic mimicry. The stage of the virus lifecycle facilitated by apoptotic
mimicry is listed along with any PS receptors known to be engaged by the various viruses. Refer to text for details and associated references
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exposure.90 Apoptotic promastigote forms can be observed in
axenic cultures and in the gut of the sand-fly vector. In each
situation PS exposure contributes to parasite infectivity.
Since its description in 2001, apoptotic mimicry, particularly
PS exposure, has been implicated in the establishment of
various intracellular protozoan infections, including modifying
host immune function through the production of IL-10 and
TGF-β.91 The infective inoculum of Toxoplasma gondii
parasites comprise two different populations of tachyzoite
forms, PS-exposing and non-exposing ones, that cooperate
to establish infection in a similar way to what happens
with Leishmania promastigotes.92 Interestingly, in this case
PS-exposing tachyzoites are responsible for disease
dissemination.92 The infective trypomastigote forms of Trypa-
nosoma cruzi, subvert the inflammatory capacity of macro-
phages by activating Smad 2 nuclear translocation and
inducible NO synthase enzyme degradation in host cells.
Unlike the T. cruzi amastigote and epimastigote forms,
the evolutive form is the only form that is capable of
exposing PS.93
The molecular mechanism involved in PS exposure in
pathogenic trypanosomatids is just beginning to be unraveled.
Although it is not yet clear whether Xkr8 and TMEM16 are
phylogenetically conserved in these organisms, Campos-
Salinas et al.94 recently described the functionality of a novel
ABC transporter in PS externalization in three different
species of Leishmania spp. A functional defect in this
translocase decreased PS exposure in promastigotes94 that
correlated with the loss of parasites’ infectivity in a murine
model of experimental leishmaniasis.
The obligate intracellular pathogen Leishmania major
survives and multiplies in professional phagocytes. Intrigu-
ingly, the infection process of Leishmania is based on two
steps, both governed by PS. A mixture of PS+ and PS−
promastigotes enters the host body at the site of the sand-fly
bite/needle injection. (i) Within 1–3 h, PS+ or PS+ together
with PS− promastigotes, but not PS− promastigotes alone, are
engulfed silently by neutrophils. These infected neutrophils,
undergo apoptosis and expose PS, thus promoting immune
evasion (ii) PS+-infected neutrophils and their apoptotic
PS+ remnants recruit professional phagocytes, the preferred
host cells for intracellular replication. Silent clearance by
circulating monocytes and tissue resident macrophages,
allows leishmania promastigotes to enter their replicatory
state (amastigotes) within monocytes undetected by immune
surveillance95 (Figure 4e). Presently, studies employing
leishmania are among the best understood models of protist
apoptotic mimicry.
Externalized PS is Dysregulated in the Tumor
Microenvironment
As noted above, the non-immunogenic properties of apoptotic
cells can be hijacked by tumor cells to escape immune
detection by creation of a local immunosuppressive environ-
ment that is defined by the presence of IL-10, TGF-β, soluble
FAS and FAS-ligand. In addition to the increased burden of
apoptotic cells, pro-inflammatory and adaptive immune
response are suppressed in the tumor microenvironment by
the presence of (i) immature tumor vasculature,96 (ii) tumor-Ta
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derived exosomes,18 and (iii) viable tumor cells,16 all of which
express PS (Figure 6). Moreover, intra-tumoral DCs that
bind and ingest PS-expressing cells maintain an immature
phenotype preventing the expression of co-stimulatory mole-
cules that are required for optimum functional antigen
presentation.97 PS exposure on microvesicles (exosomes)
derived from patient tumor samples also suppress activation
of T-cell responses.98 In addition, PS is markedly increased in
tumors in response to chemo- and radiotherapy, which further
enhances PS-mediated immunosuppression.
Function of PS Receptors in Cancer Microenvironment
PS receptors, including the TAM and TIM family of receptors,
are expressed on infiltrating myeloid-derived cells where they
function to promote tissue homeostasis following inflammatory
signaling. In the tumor microenvironment these receptors are
engaged by PS or PS bridging molecules resulting in the
expression of immunosuppressive cytokines and the preven-
tion of a productive anti-tumor immune response. Mertk and
Axl are expressed on infiltrating macrophages and DCs, but
also frequently expressed on the tumor cells themselves.99
This combined effect of PS and PS receptors may provide a
‘perfect storm’ that accentuates immune escape. Indeed,
elegant experiments by Cook and colleagues showed that
transplantation of monocytes from Mertk− /− mice into
irradiated tumor-bearing mice support a more favorable anti-
tumor response compared to transplantation of wild-type
monocytes. This was characterized by decreased levels of
IL-10 and increased numbers of tumor-infiltrating lympho-
cytes, a general feature of improved tumor immunity.100
Further studies showed that Mertk-dependent efferocytosis
of apoptotic mammary cells by Mertk+-infiltrating macro-
phages during breast involution is associated with TGF-β
production and increased metastatic frequency of primary
breast carcinoma.101 As Mertk-dependent efferocytosis
requires the vitamin K-dependent PS-binding protein Gas6
for activation, these studies suggest that PS and PS receptors
are drivers of both metastatic disease and immune escape.
Because warfarin antagonizes GAS6-mediated activation,
low dose Warfarin therapy during pregnancy may reduce
pregnancy-associated breast cancer progression. This con-
cept is supported by recent studies showing Axl-dependent
anti-metastatic activity of warfarin in other solid tumor models,
including pancreatic cancer.102
Pre-clinical PS Targeting Agents in Cancer and Infectious
Disease; Annexin A5 and mAbs
The above-mentioned dysregulation of PS in the tumor
microenvironment suggests that strategies that inhibit PS
signaling thereby preventing PS-mediated immune suppres-
sion in tumors are attractive. In fact, PS blocking strategies
may function akin to immune checkpoint inhibitors, much the
same way that blockade of PD-L1 and CTLA4 operate to
prevent inhibitory signals in T cells.103 Indeed, early pre-
clinical studies with Annexin A5 (AnxA5), a natural occurring
ligand for PS, support this idea.104 Interestingly, the inter-
actions of AnxA5 with apoptotic monocytes proceed in a
cooperative manner in the presence of calcium, whereas
binding to necrotic as well as viable monocytes does not. As
mentioned above, the higher lateral mobility of PS on dying
cells may allow binding of a critical density of AnxA5 to
saturate and block exposed PS, or it may allow clustering of
PS molecules that enhance their signaling capabilities.
Systemic administration of AnxA5 or other PS ligands
may slow tumor progression by blocking the tumor-supportive
properties of apoptotic cells and tumor-derived micro-
vesicles.105 In combination with radio- or chemotherapy,
AnxA5 could be used as a natural adjuvant to increase the
immunogenicity of dying tumor cells thereby promote an anti-
tumor immune response.106 This may be especially helpful in
targeting cancer cells that have resisted therapy and are thus
prone to recurrence and metastases. Incubation of apoptotic
cells with AnxA5 prior to immunization has been shown to
significantly increase the immunogenicity of these cells.107
Thus, the disruption of the PS-derived signals of apoptotic
tumor cells by AnxA5may trigger a pro-inflammatory response
Figure 5 Apoptotic death versus apoptotic mimicry during leishmanial infection and establishment. Metacyclic promastigotes accumulate in the sand-fly hindgut. The infective
inoculum contains live parasites together with morphologically and biochemically characterized apoptotic parasites. The presence of apoptotic and viable parasites is necessary
for the establishment of the infection. Live parasites infect host cells, whereas dead parasites downregulate the production of nitric oxide (left panel). In the mammalian host,
amastigote forms disseminate the disease and expose PS at their surface without any other phenotype of apoptotic death (center panel). PS recognition by the macrophage leads
to an active anti-inflammatory response, mainly characterized by TGF-β and IL-10 production. This generates a feedback effect leading to increased macrophage deactivation
and parasite proliferation. Susceptible mice strains upregulate PS exposure on intracellular amastigotes by a mechanism yet to be defined (right panel)
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contributing to a specific immune reaction against the tumor
cells. Interestingly, AnxA5 decreased apoptotic cell uptake by
peritoneal macrophages, increased their uptake by DCs, and
heightened the immunogenicity of irradiated lymphoma
cells in vivo.97,108,109 The fact that AnxA5 has been shown to
serve as an adjuvant for apoptotic tumor cells by blocking
PS-dependent signals in phagocytes,97 supports the further
development of annexin proteins as PS antagonists.
With respect to the role of AnxA5 in infectious diseases, the
infectivity of HIV-1 for humanmacrophages is decreased in the
presence of AnxA5.106 Moreover, PS and a non-phospholipid
component of the Hepatitis B virus (HBV) envelope are
involved in AnxA5 binding and HBV infection.110 The disrup-
tion by AnxA5 of PS-mediated signals might be utilized for
therapeutic interventions in a multitude of infectious diseases
in which apoptotic mimicry causes silent phagocytosis
of – and tolerance to – the pathogenic agent (see above).
PS-targeting Antibodies
A panel of PS-targeting antibodies that bind to PS with high
affinity, either directly or when complexed to the serum protein
β2-glycoprotein I (β2GP1), were first developed by Phil
Thorpe’s laboratory.111,112 Many of these antibodies bind to
exposed PS by cross-linking two molecules of β2GP1 thus
stabilizing its interaction with externalized PS. Pre-clinical
tumor studies showed that the PS-targeting antibodies
3G4, 2aG4 and chimeric 1N11 (mch1N11) localize to
PS-expressing tumors and tumor blood vessel endothelial
cells, eliciting strong anti-tumor effects when combined with
chemo- or radiotherapy (Figure 7 and Table 2). As PS
exposure on tumor vasculature was found to be an exquisitely
selective marker of endothelial cells in the tumor
microenvironment,96 these antibodies can be used as
vascular targeting agents. However, rather than being limited
to the use as delivery vehicles, the antibodies were also found
to have anti-tumor activity.91 Furthermore, antibody-mediated
blockade of PS signaling dramatically enhanced the activity of
standard therapies in multiple pre-clinical tumor models.113,114
Evaluation of the tumor vasculature after antibody-mediated
PS blockade revealed accumulation of macrophages around
tumor blood vessels and subsequent vascular destruction akin
to antibody-dependent cellular cytotoxicity114 (Figure 7).
Further exploration revealed that irradiation in combination
with antibody-mediated PS targeting resulted in long-term
durable responses in a syngeneic rat brain tumor model.
Figure 6 PS targeting antibodies selectively target the tumor microenvironment. Localization of near-infrared (NIR)-labeled Bavituximab F(ab)2 to orthotopically implanted
PC3 prostate tumor in male SCID mice. Animals were injected with 25 μg NIR-PGN650 (a) or NIR-control IgG F(ab’)2 (b). Fluorescent imaging was conducted 24 h following
injection of NIR-labeled antibodies. Anti-PS antibodies specifically localize to tumor blood vessels (c)
PS is a global immunosuppressive signal
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These results were particularly striking as long-term respon-
ders were immune to rechallenge with the same tumor cells
implanted contralaterally in the brain.114 Subsequent studies
have demonstrated in pre-clinical models of prostate cancer
that antibody-mediated PS blockade reprograms the innate
immune system to promote anti-tumor responses. Additional
pre-clinical studies have further delineated multiple measure-
ments of immune activation in the tumor microenvironment
mediated by 2aG4, including the increased production of
inflammatory cytokines, reduction of immunosuppressive
myeloid-derived suppressor cells (MDSCs), and an increase
in tumor-fighting M1 macrophages and mature DCs that lead
to the induction of tumor-specific cytotoxic T cells.115 Recently,
studies in immune competent mice bearing breast cancer or
melanoma revealed that the combination of PS-targeting
(mch1N11) and immune checkpoint antibodies (anti-PD-1 and
anti-CTLA-4) showed greater anti-tumor effects than single
agent therapy. Combination therapy enhanced the levels of
CD4+ and CD8+ tumor-infiltrating lymphocytes, elevated the
fraction of cells expressing the pro-inflammatory cytokines
IL-2, IFN-γ, and TNF-α and increased the ratio of CD8 T cells to
MDSCs and Tregs in tumors. Similar changes in immune cell
profile were observed in splenocytes. Taken together, these
data show that antibody-mediated PS blockade enhances the
anti-tumor efficacy of immune checkpoint inhibition.
Clinical PS-Targeting: Bavituximab
The above-mentioned pre-clinical studies supported the
development of a PS-targeting antibody, bavituximab, which
is currently being assessed in multiple clinical trials116–118 and
planned clinical studies to evaluate the therapeutic efficacy of
bavituximab in combination with an anti-PD-L1 antibody for
the treatment of solid tumors. Bavituximab is a chimeric
monoclonal antibody constructed from the v region (Fv) of the
murine antibody 3G4, used in extensive pre-clinical studies,
joined to the c region (Fc) of a human IgG1. Bavituximab, like
3G4, binds to PS via β2GPI. The antibody has been
administered to over 700 patients in clinical trials evaluating
the antibody as monotherapy and in various combination
regimens in patients with multiple cancers, chronic hepatitis C
virus andHIV infection. To date, studies have shown promising
signs of activity and an acceptable safety profile (Table 2).
Moreover, bavituximab has been evaluated in several
investigator-sponsored trials that include Her2-negative
breast cancer, non-small cell lung cancer (NSCLC), hepato-
cellular carcinoma, rectal carcinoma, advanced melanoma,
and castrate-resistant prostate cancer. Finally, bavituximab is
currently being evaluated in SUNRISE (‘Stimulating ImmUne
RespoNse thRough BavItuximab in a PhaSE III Lung Cancer
Study’), a global randomized, double-blind, placebo-controlled
registration trial sponsored by Peregrine Pharmaceuticals
Healthy Cell Tumor Environment         + PS Targeting Antibody
= Phosphatidylserine (PS)
PS is maintained on the interior 
leaflet of a cell’s plasma membrane
PS not available for binding
PS becomes exposed on tumor blood 
Vessel cells, tumor cells and microvesicles 
due to stress, cytokines
Damage to tumor by chemotherapy,
radiation and targeted therapies 
results in additional PS exposure 
PS receptors on immune cells engage PS,
resulting in highly immunosuppressive 
signaling. 
Known PS receptors:
• TIM receptors: (TIM-1, TIM-3, TIM-4)
• TAM receptors: (Axl, Mer, Tyro-3) 
• Others: CD300a, RAGE, BAI-1, Stabilin
Immuno-suppressive effects:
• Increased TGF-β, IL-10
• lack of immune activation
“Applying the Accelerator”
Antibody ( Y ) targets PS
Antibody-mediated blocking of PS
stimulates immune activation through 
Fcγ receptor cross-linking
Immuno-stimulatory effects:
• Increased TNF-α, IL-12
• Reduced MDSC
• M2 to M1 macrophage polarization
• Maturation of dendritic cells
• Antigen-specific T-cell response
• Innate immune response (ADCC)
Fcγ Receptors: Initiation 
of signaling receptor cross-linking
Immune Modulating Cell
(MDSC, macrophage, T-cell)
XXX
Y
FcγR
FcγR FcγR
FcγR
“Removing the Brakes”
Antibody ( Y ) targets PS
PS receptors are inhibited from 
engaging PS
Antibody-mediated blocking of PS
overrides PS-mediated 
Immunosuppressive signaling
Immuno-stimulatory effects:
• Decreased TGF-β, IL-10
• Reduced  myeloid derived 
suppressor cells (MDSC)
PS Receptors: Immuno-Suppressive
TIMs    TAMs     others                      TIMs      TAMs   others            
Figure 7 Antibody-mediated blockade of the PS signaling pathway in the tumor microenvironment. As described in the text, PS is highly dysregulated in the tumor
microenvironment by the combined action of a oxidative stress and immature tumor vasculature, the secretion of PS-positive tumor exosomes, and the high apoptotic index of
proliferating tumors. PS-targeting antibodies are thought to bind externalized PS and interfere with the inhibitory functions of PS in the tumor microenvironment by inhibiting PS
binding to PS receptors and by Fcγ-mediated ADCC. The net effect is to activate immunogenic signals in the tumor microenvironment
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(Tustin, California, USA). The SUNRISE trial will assess
bavituximab plus docetaxel versus placebo plus docetaxel in
582 patients with previously treated locally advanced or
metastatic NSCLC.
Future Perspectives
Although initially characterized as one of the emblematic
signals associated with apoptosis, externalized PS on the
surface of the apoptotic cell provides a global immunosup-
pressive signal that dampens local and systemic immunity.
This pathway appears to be an evolutionarily conserved
mechanism of (higher) metazoans to protect from autoimmune
complications when routinely disposing of dying host cells.
These signals appear to be breached in autoimmunity, and
subverted in viral and protist infection as apoptotic mimics.
Themultitude of genetically diverse pathogens that have been
shown to similarly hijack this fundamental immunosuppres-
sive pathway support a broad ‘apoptotic mimicry’ paradigm of
pathogenesis and the hypothesis that evolution may have
selected for pathogens that steer immune modulating cells
toward such ‘survivable’ behavior. Moreover, PS appears to be
universally dysregulated in cancers, and along with the
upregulation of PS receptors, provide potent immunosuppres-
sion in the tumor microenvironment. The large amount
of evidence obtained with AnxA5 and PS-targeting anti-
bodies supports the notion that PS is a fundamental immune
checkpoint akin to or upstream of the CTLA4 and PD-1/
PD-L1 checkpoints. Late-stage clinical trials evaluating
the PS-targeting antibody, bavituximab, are in progress in
multiple oncology indications, while agents targeting PS
receptors are in various stages of pre-clinical and clinical
development.
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